EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Executive Summary
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
You may also be interested in...
Here At Last: New EU Annex On Sterile Drug Manufacturing Targets Contamination & Risk
Following two public consultations and many thousands of comments, the revised GMP Annex 1 has finally been published.
Final Revisions Should Ease Global Use Of EU GMP Annex I Sterile Drugs Guidance, Associations Say
Inter-associations working group suggests changes to the EU GMP Annex I revision to make it easier to understand by health authorities worldwide; the groups point out that the annex will be used globally and not just in Europe.
EU GMP Annex I Proposal Would Maintain PUPSIT, Relax WFI Restrictions
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.